Skip to main content
Radcliffe Medical Education
Medical education learning resources for healthcare professionals
Radcliffe Medical Education banner
Radcliffe Medical Education banner
  • Home
  •  Managing Hypertension in CVD: How Low Can We Go?

Managing Hypertension in CVD: How Low Can We Go?

Topic:
  • Guidelines
  • Prevention

Available Credit:

  • 1.00 EBAC

Course Published On:

Course Expiry Date:

Managing Hypertension in CVD: How Low Can We Go?
No ratings

Overview

This virtual educational programme offers a comprehensive CME-accredited course for healthcare professionals managing hypertension in patients with cardiovascular disease. 

 

Chaired by Dr Yassir Javaid (Imperial College Healthcare NHS Trust, London, UK), with Prof Michel Burnier (University Hospital of Lausanne, Lausanne, CH), Prof Mariya Tokmakova (Medical University of Plovdiv, Plovdiv, BG) and Prof Reinhold Kreutz (Charite University Medicine, Berlin, DE), the expert faculty explores how to identify and classify very high-risk patients, interpret the CVD–hypertension link and apply current guideline-directed approaches, including the latest ESH recommendations. 

 

Emerging questions in hypertension management are addressed, including the potential role of cardiovascular risk-driven treatment initiation, the evolving use of beta blockers and strategies to improve long-term adherence. 

Support Statement

This programme is supported by an unrestricted educational grant from Merck Healthcare KGaA (Darmstadt, Germany).

Disclosure

In compliance with EBAC guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.  

 

The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities. 

Terms & Conditions

Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable. 

 

The session, ‘Managing Hypertension in CVD: How Low Can We Go?’ is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit. 

 

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS). 

 

Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. 

Instruction to Participants

There is no fee for taking part in this online learning activity. 

 

Activities are designed to be completed within 60 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame. 

 

To complete the course and claim certification participants must: 

 

  • Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
  • Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion. 

Target Audience

  • Cardiologists
  • Hypertension Specialists
  • Primary Care Physicians
  • Allied Healthcare Professionals Involved in Cardiovascular Care

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Describe the link between CVD and hypertension
  • Classify hypertension patients according to their cardiovascular risk
  • Recall recent guideline-directed and evidence-based strategies for managing very high CVD risk patients
  • Apply guideline-directed and evidence-based management strategies to a case study
  • Use expert guidance to adopt optimal multidisciplinary antihypertensive management strategies in patients with very high cardiovascular risk

Module

Title

Duration

Speakers

Session 1 Introduction 4m 2s Yassir Javaid Michel Burnier Mariya Tokmakova Reinhold Kreutz
Session 2 Understanding and Defining the Link Between CVD and HTN 11m 3s Michel Burnier
Session 3 Stratifying According to Risk and Outcome Data 12m 27s Mariya Tokmakova
Session 4 Guideline-directed Management of Very High-risk Patients 11m 39s Reinhold Kreutz
Session 5 Case Presentation and Discussion 17m 35s Yassir Javaid Michel Burnier Mariya Tokmakova Reinhold Kreutz
Session 1.
Session 2.

Understanding and Defining the Link Between CVD and HTN

Duration: 11m 3s

Speakers: Michel Burnier

Session 3.

Stratifying According to Risk and Outcome Data

Duration: 12m 27s

Speakers: Mariya Tokmakova

Session 4.

Guideline-directed Management of Very High-risk Patients

Duration: 11m 39s

Speakers: Reinhold Kreutz

Session 5.

Case Presentation and Discussion

Duration: 17m 35s

Speakers: Yassir Javaid Michel Burnier Mariya Tokmakova Reinhold Kreutz

Chair

Yassir Javaid

Northamptonshire CCG, UK

Dr Yassir Javaid, Cardiovascular & Diabetes Lead Northamptonshire CCG, UK. Qualified from Cambridge University and completed his VTS training in Northampton.

View full profile

Speaker

Michel Burnier

University Hospital of Lausanne, CH

Professor Michel Burnier is an internationally respected physician and academic based in Switzerland. He is Emeritus Professor of Medicine and former Head of the Division of Nephrology and Hypertension at the University Hospital of Lausanne.

View full profile
Mariya Tokmakova

Mariya Tokmakova

Division of Cardiology, First Department of Internal Diseases, Medical University of Plovdiv, Clinic of Cardiology, Universitetska Mnogoprofilna Bolnitsa Za Aktivno Lechenie Sveti Georgi Enolichno Aktsionerno Druzhestvo, Plovdiv, Bulgaria

Prof Mariya Tokmakova is Vice-Rector for Scientific and Research Activities at the Medical University of Plovdiv, where she also serves as Head of the Cardiology Clinic at University Hospital St Georgi and is a member of the Academic Staff at the Department of Cardiology.

View full profile
Reinhold Kreutz

Reinhold Kreutz

Charite University Medicine, Berlin, Germany

Prof Reinhold Kreutz is Director of the Department of Clinical Pharmacology and Toxicology at Charité – Universitätsmedizin Berlin (DE) and Professor of Hypertension and Clinical Pharmacology.

View full profile
1.00 EBAC

Managing Hypertension in CVD: How Low Can We Go?'s programme has been accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 CME point, equating to 1 hour of learning. Physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™.

Related Courses

Translating Aortic Stenosis Guidelines Into Practice: Evidence-Based Decisions for the Heart Team
  • 1.00 EBAC

Learning objectives

  • Recall recent guideline recommendations for the management of aortic stenosis
  • Summarise the evidence supporting TAVI across the sub-groups of aortic stenosis, age and surgical risk
  • Develop an expert guided approach to patient selection and referral for TAVI
  • Adopt an evidence-based approach for the lifetime management of younger patients with aortic stenosis
See more
Revolutionising Thrombosis Treatment in ACS, SSP and AF
  • 1.00 EBAC

Learning objectives

  • Discuss the unmet needs in thrombosis management, MACE burden after ACS, stroke in AF and secondary stroke prevalence and consequences
  • Evaluate the current standard of care for the treatment of ACS, SSP and AF and its limitations
  • Review guidelines and critique current prescribing practices and the implications of inadequate treatment
  • Explain the different strategies for targeting FXI and how FXI inhibition mechanisms differentiate from traditional anticoagulation therapies
  • Identify emerging anticoagulant strategies and describe the efficacy and safety data from Phase 2 FXI inhibitor clinical trials as well as ongoing Phase 3 trials and potential place in therapy for ACS, AF and SSP
  • Apply evidence-based anticoagulation strategies by optimising treatment decisions and addressing patient-specific risk factors
See more
Advancing Patient Care in Hypertrophic Cardiomyopathy
  • 0.50 AMA PRA Credit

Learning objectives

  • Recall recent trial data for novel disease modifying therapy in HCM
  • Describe the evolving guideline directed approach to managing HCM
  • Develop an expert-led approach to implementing novel therapy in clinical practice
See more